MOVEMENT DISORDERS: Edited by Kailash P. BhatiaContinuous dopaminergic stimulation therapy for Parkinson's disease – recent advancesTimpka, Jonathana,b; Mundt-Petersen, Ulrikaa,b; Odin, Pera,b,c Author Information aDepartment of Clinical Sciences Lund, Faculty of Medicine, Lund University bDepartment of Neurology, Skåne University Hospital, Lund, Sweden cDepartment of Neurology, Central Hospital, Bremerhaven, Germany Correspondence to Jonathan Timpka, Restorative Parkinson Unit, Alwallhuset, SUS, Barngatan 2 A, Plan 1, SE-222 42 Lund, Sweden. Tel: +46 737332384; e-mail: [email protected] Current Opinion in Neurology: August 2016 - Volume 29 - Issue 4 - p 474-479 doi: 10.1097/WCO.0000000000000354 Buy Metrics Abstract Purpose of review We aim to review the most interesting recent advances on the clinical aspects of continuous dopaminergic stimulation in Parkinson's disease. Recent findings Several large, open-label studies have presented data that are in line with the randomized controlled trial on L-dopa-carbidopa intestinal gel infusion, which shows that a continuous drug delivery can improve motor fluctuations and dyskinesia in patients with advanced Parkinson's disease. Furthermore, new extended-release formulations of L-dopa aim to stabilize plasma concentrations and thus reduce the degree of motor complications – despite a reduced number of daily doses. Transdermal rotigotine has been shown to be effective for specific subgroups of patients, although the general effect on nonmotor symptoms is still unclear. New products for L-dopa infusion are also at different stages of development, but the routes of administration are widely different: intrajejunal, subcutaneous, and oral. Summary The understanding of the mechanisms behind the complications of long-term L-dopa treatment is still not complete, but therapies aiming for continuous dopaminergic stimulation are already widely used in clinical practice and the evidence strength is improving. However, there is still an urgent need for both less invasive and less costly options in order to increase access to these therapies. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.